UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 14, 2014
Ultragenyx Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware |
| 001-36276 |
| 27-2546083 |
(State or other jurisdiction |
| (Commission |
| (I.R.S. Employer |
60 Leveroni Court, Novato, California |
| 94949 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (415) 483-8800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On August 14, 2014, the Company updated its corporate presentation, a copy of which is attached hereto as Exhibit 99.1 and incorporated by reference herein.
(d) Exhibits
Exhibit |
| Description |
99.1 |
| Corporate Presentation, dated August 14, 2014 |
* * *
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2014 | Ultragenyx Pharmaceutical Inc. | ||
|
|
| |
| By: |
| /s/ Shalini Sharp |
|
|
| Shalini Sharp |
|
|
| Senior Vice President, Chief Financial Officer |
- 3 -
Exhibit Index
Exhibit |
| Description |
99.1 |
| Corporate Presentation, dated August 14, 2014 |
- 4 -